Kazia Therapeutics Ltd Sponsored ADR (KZIA)
NASDAQ (CM) NASDAQ (CM) Primary Summary
KZIA Chart
Why Is Brain Cancer-Focused Kazia Therapeutics Stock Trading Lower On Tuesday?
Kazia Therapeutics Limited KZIA stock is trading lower on Tuesday after the company provided a regulatory update on paxalisib for glioblastoma (GBM) following its Type C clinical meeting with the FDA.
Kazia Therapeutics Stock: Is KZIA a Buyout Candidate in the Making?
Australian biotech company Kazia Therapeutics (NASDAQ: KZIA ) stock rocked the market after reporting encouraging results from a Phase II/III trial for its glioblastoma brain cancer therapy Paxalisib. The positive results extended the life of patients by over three months compared to the current standard of care.
Biotech Stock Laboratory: Try a Small Experiment With Kazia Therapeutics
Biotechnology stock traders, listen up! Do you like to roll the dice and take your chances on promising drug developers?
Kazia Therapeutics Ltd Sponsored ADR Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Point72 Asset Management LP Point72 Asset Management LP | 200,000 | $1.38M | $2.72M | $1.34M | 97.1% |
 Matthew Okkerse Dauntless Investment Group LLC | 79,832 | $593,949.77 | $1.05M | $452,248.59 | 76.14% |
Kazia Therapeutics Ltd Sponsored ADR Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Sean Lee HC Wainwright & Co. | - | - | - | - | - |
Kazia Therapeutics Ltd Sponsored ADR (KZIA) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Kazia Therapeutics Ltd Sponsored ADR ever had a stock split?
Kazia Therapeutics Ltd Sponsored ADR Profile
| Biotechnology Industry | Healthcare Sector | John Friend CEO | NASDAQ (CM) Exchange | 48669G303 CUSIP |
| AU Country | 6 Employees | 14 Jul 2017 Last Dividend | 17 Apr 2025 Last Split | 6 Jan 1999 IPO Date |
Overview
Kazia Therapeutics Limited is a biotechnology entity focused on the development of anti-cancer drugs, showcasing a dynamic approach in the treatment of various cancers. Originally established in 1994 as Novogen Limited, the company underwent a significant rebranding to Kazia Therapeutics Limited in November 2017, signifying a renewed focus on its innovative therapeutic solutions. Operating from its headquarters in Sydney, Australia, Kazia has positioned itself as a pioneer in the oncology sector, leveraging cutting-edge research to target some of the most challenging forms of cancer through its advanced drug development programs.
Products and Services
- Paxalisib
- EVT801
Kazia's flagship product, Paxalisib, is a groundbreaking inhibitor of the PI3K/AKT/mTOR pathway, crafted with precision to penetrate the brain and potentially treat a range of cancers including glioblastoma, diffuse intrinsic pontine glioma/advanced solid tumors, atypical teratoid rhabdoid tumor, brain metastases, triple negative breast cancer, and primary central nervous system lymphoma. Its development underscores Kazia’s commitment to targeting some of the most aggressive and difficult-to-treat cancers, providing hope for patients worldwide.
Expanding its oncology pipeline, Kazia is also developing EVT801, a novel small molecule inhibitor specifically targeting the vascular endothelial growth factor receptor 3 (VEGFR3). This therapeutic is designed to inhibit tumor growth by targeting the blood vessels that feed them, representing another facet of Kazia’s strategy to combat cancer through innovative and targeted therapies.
